ESR1 and breast carcinoma: For instance, reducing the expression of RBM39 can inhibit the proliferation of estrogen receptor (ER)-positive human breast cancer cells [6, 7], which further suggests that RBM39 is an important signaling molecule in the pathogenesis of breast cancer, which may bring new methods for treatment of invasive cancer [4].